Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPTN 035: BufferGel and PRO 2000/5 Gel for HIV Prevention
NCT00074425Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2005
- Primary completion
- Sep 2008
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of buffergel and PRO 2000 in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2005; status: completed.
02
Drugs
buffergelPRO 2000
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00074425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074425.